文献综述(Review)

VEGF 靶向治疗及其生物标志物在晚期结直肠癌中的研究进展

Published at: 2015年第24卷第4期

林泽鑫 1 , 劳学军 1
1 暨南大学附属第一医院 普通外科,广东 广州 510000
通讯作者 学军 劳 Email: foxlxj2k@126.com
DOI: 10.3978/j.issn.1005-6947.10.3978/j.issn.1005-6947.2015.04.021
基金:

摘要

结直肠癌(CRC)是世界范围内癌症发病与致死的主要因素,近几年分子靶向治疗的临床应用为晚期 结直肠癌治疗带来了曙光。贝伐珠单抗被批准应用于一线和二线晚期结直肠癌的治疗,促使了以血管 内皮生长因子(VEGF)为作用靶点的靶向治疗药物不断涌现,并在临床试验中取得显著疗效。笔者就 VEGF 靶向治疗及其生物标志物在晚期结直肠癌中的研究进展进行综述。


VEGF-targeted therapy for metastatic colorectal cancer and related biomarkers: recent advances

Abstract

Colorectal cancer (CRC) is a major contributor to cancer morbidity and mortality worldwide. Recently, the clinical application of molecular targeting therapy brings hope for treatment of metastatic CRC (mCRC). Following the approval of bevacizumab as first- and second-line treatment of mCRC, the therapeutic agents targeting vascular endothelial growth factor (VEGF) have been emerging constantly, and also shown significant efficacy in clinical trials. In this paper, the authors address the progress in VEGF-targeted therapy and the related biomarkers for mCRC.


comments powered by Disqus

全文

引用

引用本文: 泽鑫 林, 学军 劳. VEGF 靶向治疗及其生物标志物在晚期结直肠癌中的研究进展[J]. 中国普通外科杂志, 2015, 24(4): 575-580.
Cite this article as: LIN Zexin, LAO Xuejun . VEGF-targeted therapy for metastatic colorectal cancer and related biomarkers: recent advances[J]. Chin J Gen Surg, 2015, 24(4): 575-580.